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ABSTRACT 
Synthetic nucleobase- and nucleoside-analogs have stood the test of time and remain a 
cornerstone in the treatment regimen against various forms of cancer. Due to their 
resemblance to endogenous nucleotides these antimetabolites interfere with cellular 
pathways, including nucleotide metabolism, as well as DNA and RNA synthesis. However, 
the treatment efficacy of nucleobase- and nucleoside-analogs can be hampered by 
“house-cleaning” enzymes involved in sanitation and balance of the nucleotide pool. In this 
work, we validated whether targeting nucleoside triphosphate hydrolases, involved in 
sanitation of the nucleotide pool, is a promising strategy to improve the efficacy of commonly 
used nucleobase- and nucleoside-analogs. These include: 
1. dUTPase to potentiate 5-fluorouracil treatment 
2. dCTPase to potentiate decitabine treatment 
3. NUDT15 to potentiate 6-thioguanine treatment 
We characterized dUTPase, dCTPase and NUDT15 by various biochemical and biophysical 
techniques and assessed their role in intracellular nucleotide homeostasis using RNA 
interference. Through the development and use of small molecule inhibitors targeting these 
hydrolases, we highlighted the benefit of inhibiting nucleotide pool sanitization to improve 
nucleobase- and nucleoside-analog therapy.  
In Paper I we demonstrated that dUTPase inhibition reinforces 5-fluorouracil-induced 
replication defects and cytotoxicity. With this study, we contributed to the characterization of 
dUTPase inhibitors and increased our understanding of the mode of action of this 
combination treatment.  
In the second study (Paper II), we developed small molecule inhibitors against dCTPase to 
explore the biological function of this nucleoside triphosphate hydrolase in the context of 
endogenous nucleotide homeostasis and decitabine treatment. We showed that chronic 
inhibition of dCTPase has a cytostatic effect on cancer cells and potentiates cellular effects of 
decitabine therapy.  
Targeting enzymes involved in sanitation of the oxidized nucleotide pool is a novel treatment 
strategy that exploits the dysregulated reduction-oxidation environment of tumors. Based on 
the increasing attention to MTH1 as a prime example for this approach, we validated whether 
the sequence homolog NUDT15 (also known as MTH2) fulfills comparable enzymatic 
functions, making it a potential target for cancer therapy. With extensive biochemical and 
cellular experiments we demonstrated that NUDT15 possesses only minimal activity with 
oxidized nucleotides and is non-essential for cancer cell survival (Paper III). While assessing 
the cellular function of NUDT15, we discovered activity with the thiopurine effector 
metabolites, 6-thio-dGTP and 6-thio-GTP.  
In light of several pharmacogenetic studies, which link thiopurine hypersensitivity to the 
NUDT15 R139C variant, we further elucidated the role of NUDT15 (wild type and mutants) 
in thiopurine metabolism (Paper IV). We combined biochemical analyses with cellular 
experiments on genetically modified cell lines to demonstrate that NUDT15 has a strong 
preference for thiolated guanine substrates and that this activity counteracts thiopurine 
efficacy in cancer cells. Furthermore, we propose that the observed hypersensitivity of 
NUDT15 R139C positive patients is not caused by impaired enzymatic activity, but is a result 
of untenable protein stability.  
Inspired by these findings, we developed first-in-class NUDT15 inhibitors and validated 
whether pharmacological inhibition of NUDT15 is a promising strategy to sensitize leukemia 
cells to thiopurine treatment (Paper V). NUDT15 inhibition significantly increased the 
availability of thiopurine nucleoside triphosphates, leading to potentiation of DNA 
incorporation, DNA damage and cytotoxicity.  
Overall, these studies demonstrated that preventing the sanitation of nucleotide-analogs, by 
inhibiting nucleoside triphosphate hydrolases, is a promising strategy to improve the efficacy 
of nucleobase- and nucleoside-analog treatments.  
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INTRODUCTION 
The genetic composition and the epigenetic make-up are important factors influencing the 
blueprint and function of a cell. To guarantee correct cell performance and avoid disease it is 
of vital importance to keep the genetic and epigenetic information of a cell intact. Our DNA 
and the molecular DNA precursors are constantly exposed to various exogenous and 
endogenous hazards that can irrevocably damage the hereditary information [1]. 
Accumulation of genetic mutations is one of the major causes for neoplastic diseases, which 
today are a major cause of death in the western world [2]. Along with surgery and radiation 
therapy intervention with pharmaceutical agents is a component of almost every anti-cancer 
treatment regimen. One of the oldest cancer treatment strategies is the use of synthetic 
nucleobase- and nucleoside-analogs (antimetabolites) to disturb nucleotide homeostasis and 
genome integrity, which even today remains a cornerstone treatment against many forms of 
cancer [3]. Due to their resemblance to endogenous molecular building blocks, these agents 
interfere with various cellular pathways, including nucleotide metabolism, as well as DNA 
and RNA synthesis [3]. Among the oldest and most commonly used nucleobase- and 
nucleoside-analogs are 5-fluorouracil (5-FU), decitabine (5-aza-dC) and 6-thioguanine 
(6-TG) [4-6]. However, dose-limiting side effects due to poor cancer cell selectivity, 
long-term toxicity and often occurring drug resistance are major disadvantages associated 
with these treatments [3]. To be able to increase the therapeutic success it is important to 
understand the complexity of endogenous and synthetic (d)NTP metabolism. The treatment 
efficacy of nucleobase- and nucleoside-analogs can be hampered by the activity of 
“house-cleaning” enzymes involved in sanitation and balance of the nucleotide pool. This 
work elucidates the importance of the nucleoside triphosphate hydrolases dUTPase, dCTPase 
and NUDT15 for cellular integrity, both alone and in the context of nucleobase- and 
nucleoside-analog treatment.  
  
 2 
1.1 The importance of genome integrity 
Life on Earth appears immensely diverse, ranging from single cell organisms to complex 
multicellular compositions like the human body. Even though they all seem extraordinarily 
unalike, in fact all living organisms are composed of a common single unit, the cell [7]. The 
hereditary blueprint of each cell is stored in the form of a complementary nucleotide double 
helix, better known as deoxyribonucleic acid or DNA. The sequence of the bases along the 
sugar-phosphate backbone creates a unique code that stores the information for protein 
composition, much like the alphabet is a code that creates each word in this thesis. In a 
process termed transcription, the code of a DNA segment (gene) is copied to a 
complementary ribonucleic acid (RNA) strand. Whereas both, DNA and RNA, are nucleotide 
polymers, RNA differs from DNA by 1) the sugar; ribose instead of deoxyribose and 2) the 
composition of the nucleobases; replacing thymine with uracil. Guided by the three letter 
code of the RNA, ribosomes align one out of 20 amino acids to form proteins, in a process 
called translation. Besides the sequence of the nucleobases in the DNA, which determines 
the protein composition, it is the regulation of gene expression that creates distinct cell 
populations and unique organisms.   
Chemical reactions, including oxidation, methylation or deamination, caused by exogenous 
and endogenous sources are a constant threat to the fundamental genetic information [1]. 
These include reactive oxygen and nitrogen species (ROS, RNS), UV radiation and 
chemicals. Even though the 3 billion base pair long macromolecule is supercoiled and highly 
protected by the nuclear membrane it is estimated that a human cell is confronted with 10
5
 
DNA lesions on a daily basis [8]. During replication DNA polymerases insert, guided by the 
base-pairing rules, free nucleotide triphosphates along the parent strand to create a 
complementary daughter strand. While DNA polymerases are highly selective against 
ribonucleotides, they often possess limited selectivity towards the nitrogenous base [9-11]. 
The high chemical liability of the free nucleotide pool, which is needed for DNA synthesis 
and repair, is therefore a significant hazard for the integrity of the genetic information [12, 
13]. 
In order to preserve the genetic information and maintain cellular fitness the cell has 
developed numerous protective mechanisms that 1) prevent utilization of erroneous 
nucleotides and 2) repair damaged DNA lesions. The first group includes a variety of 
“house-cleaning” enzymes that sanitize and balance the nucleotide pool of potentially 
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deleterious metabolites, e.g. by hydrolysis of the triphosphate chain. If the amount of 
hazardous precursors exceeds the “house-cleaning” performance of these enzymes, 
incorporation of damaged nucleotides into nascent DNA is inevitable. For this scenario the 
cell has developed a complex network of biochemical pathways that detect and repair 
erroneous DNA lesions. These include the action of the base-excision repair (BER) and the 
mismatch repair (MMR) machinery. With the help of damage-specific DNA glycosylases the 
BER machinery removes small, non-helix-distorting base lesions, like oxidized, alkylated or 
deaminated nucleotides or the non-canonical base U [14]. The MMR system recognizes and 
repairs erroneous base-base mismatches, as well as insertions and deletions occurring during 
DNA replication and recombination [15]. In addition to these complex machineries DNA 
damage stimulates a network of signaling events which, depending on the damage status, can 
induce cell cycle arrest, cellular senescence or even cell death. 
Despite the interplay of protective and reparative mechanisms changes in the genetic 
information are common [1]. Irretrievable alterations in the DNA, including deletions, 
insertions, substitutions and frameshift mutations, can cause expression of defective and 
redundant proteins or prevent proteins from being synthesized. Disturbed expression of 
oncogenes and tumor suppressor genes can have severe consequences for the cell including: 
self-sufficiency in growth signals, resistance to growth suppressors and cell death, replicative 
immortality, induction of angiogenesis, capability to metastasise, alterations in energy 
metabolism and evasion of immune detection [16]. If accumulated, the interplay of these 
cancer hallmarks can lead to the transformation of a healthy cell into a cancerous cell.   
Since genetic integrity is essential for cellular function and survival many chemotherapeutic 
agents have been developed that induce their cytotoxic effect through excessive DNA 
damage [17]. One of the major problems during anti-cancer therapy is the high heterogeneity 
within tumor cells [18]. A high mutator phenotype in cancer cells makes it possible for a part 
of the population to acquire compensatory mechanisms and escape the selection pressure. 
Tumor-relapse of more aggressive and treatment-resistant cells is often the devastating 
consequence. In addition to acquired drug resistance, intrinsic resistance, poor cancer 
selectivity and long-term toxicity are major problems. Understanding the mode of action of 
chemotherapeutic agents and cellular resistance mechanisms is therefore essential to achieve 
better tumor response.  
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1.2 The role of (d)NTPases in nucleotide homeostasis 
Nucleotides contain three moieties: a five carbon sugar, a phosphate (-chain) and a 
nitrogenous base (Figure 1A) [7]. Nucleotides composed of deoxyribose (C5H10O4) are 
polymerized to form DNA, whereas ribose (C5H10O5) containing nucleotides are utilized for 
RNA synthesis. On the first carbon of the pentose a nucleobase is attached through an 
N-glycosidic linkage. Nucleobases are heterocyclic compounds with double (purines) or 
single (pyrimidines) rings containing nitrogen and carbon atoms. In eukaryotic DNA the 
canonical nucleobases are guanine (G), cytosine (C), adenine (A) and thymine (T) 
(Figure 1B) In RNA uracil (U) replaces the thymine code. Addition of (deoxy)ribose to the 
base changes the nomenclature from G, C, A, T and U to guanosine, cytidine, adenosine, 
thymidine and uridine, respectively. Creation of a phosphoester bond between phosphoric 
acid and the 5’ carbon of the sugar transforms the nucleoside to a nucleotide. Sequential 
extension of additional phosphoric acids via phosphoanhydride bonds creates high energy 
nucleoside di- and triphosphates [7].  
When one thinks of the function of nucleotides, the first thought often pertains to their role as 
building blocks for DNA and RNA synthesis, both of which are essential for cellular viability 
[7]. However, phosphoryl transfer from nucleoside triphosphates plays a key role in various 
cellular functions, including signaling and energy transduction [19]. ATP, for example, is the 
main energy carrier of the cell and additionally an essential intra- and extracellularly 
signaling molecule [20, 21]. In addition, GTPases rely on hydrolysis of GTP for signal 
transduction, protein biosynthesis and translocation of proteins [19]. Furthermore, nucleotides 
make up coenzymes in oxidation-reduction reactions (NAD
+
, NADP
+
, FMN, FAD), are 
important for the synthesis of polysaccharides (UDP-glucose and ADP-glucose) and 
phospholipids (CDP and CTP) [7, 22].  
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Figure 1: Nucleotides are important for cellular function, including DNA and RNA synthesis, 
metabolism and signaling. A) Nucleotides consist of three moieties: a nitrogenous base, a sugar 
(ribose in RNA, deoxyribose in DNA) and a phosphate (-chain). B) The bases used for DNA and RNA 
synthesis can be divided into purines (adenine and guanine) and pyrimidines (cytosine, thymine 
(DNA) and uracil (RNA)). C) Nomenclature and abbreviations used in this thesis. 
 
  
Cytosine Thymine Uracil 
A C 
Adenine Guanine 
Purines 
Pyrimidines 
Phosphate 
Sugar 
Base 
B 
Nomenclature 
1. Indication of the sugar component:  
d=deoxyribose 
no prefix= ribose 
2. Abbreviation for the base: 
adenine=A  
guanine=G  
cytosine=C  
thymine=T  
uracil=U 
3. Indication of the number of phosphates: 
monophosphate=MP 
diphosphate=DP 
triphosphate=TP 
Examples:  
dGTP=2'-deoxyguanosine-5'-triphosphate 
GTP=guanosine-5'-triphosphate 
dUMP=2'-deoxyuridine-5'-monophosphate 
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Deoxynucleoside triphosphate phosphatases (dNTPases) 
A balanced and clean nucleotide pool is essential to guarantee correct DNA and RNA 
synthesis, as well as cellular metabolism and signaling. The cell controls nucleotide 
homeostasis through a complex, interconnected network of biosynthetic and catabolic 
pathways (Figure 2) [13, 23]. De novo biosynthesis of ribonucleotides involves the stepwise 
assembly of the nitrogenous purine and pyrimidine rings. In addition, degraded nucleobases 
and nucleosides can be salvaged through the action of phosphoribosyltransferases and 
nucleoside kinases, respectively [24]. Deoxyribonucleotide formation is regulated by 
ribonucleoside diphosphate reductase (RNR), which reduces ribonucleoside diphosphates 
(NDPs) to deoxyribonucleoside diphosphates (dNDPs) [25]. Multiple kinases and 
phosphatases work in concert to precisely regulate the balance and availability of (d)NTPs. 
The nuclear dNTP pool is kept in a tightly regulated metastable state, in which dGTP is often 
limited to 5% and dATP and dTTP are most abundant [26]. Compared to the 
physiochemically protected DNA molecule, the free nucleotide pool is orders of magnitude 
more susceptible to undesired chemical reactions, such as oxidation, alkylation and 
deamination [12, 13].  
One mechanism to control (d)NTP availability and nucleotide homeostasis is by cleaving the 
phosphoanhydride or phosphoester bond by (deoxy)nucleoside triphosphate phosphatases 
((d)NTPases) (Figure 2). (d)NTPases can be classified into four, structurally different 
superfamilies: trimeric dUTPases, all-α NTP pyrophosphatases, inosine triphosphate 
pyrophosphatases and the Nudix superfamily [27, 28]. In this thesis the importance of the 
hydrolases dUTPase, dCTPase and NUDT15 for nucleotide homeostasis and cellular integrity 
is validated, both alone and in the aspect of therapeutic nucleobase- and nucleoside-analog 
treatment. 
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Figure 2: Overview of the complex network regulating nucleotide homeostasis as suggested before 
the work of this thesis. Nucleotides are synthesized de novo or salvaged from existing building blocks. 
A precise balance between mono-, di- and triphosphates is essential for DNA and RNA synthesis, as 
well as cellular metabolism and signaling. (d)NTPases (orange) balance the availability of nucleoside 
triphosphate species by hydrolyzing the phosphate chain. (1) Inosine monophosphate dehydrogenase; 
IMPDH, (2) guanine monophosphate synthase; GMPS, (3) guanylate kinase; GUK, (4) nucleoside 
diphosphate kinase; NDPK, (5) adenylate kinase; AK, (6) uridine monophosphate-cytidine 
monophosphate kinase; UMP-CMPK, (7) cytidine triphosphate synthase; CTPS, (8) uridine kinase; 
UK, (9) deoxycytidine triphosphatase; dCTPase, (10) deoxythymidine monophosphate kinase; 
dTMPK, (11) SAM domain and HD domain-containing protein 1; SAMHD1. Graphical depiction 
adapted from reference [23] and [13].  
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Deoxyuridine triphosphatase (dUTPase) 
One major difference between DNA and RNA is the distinct composition of the bases, with 
thymine replacing uracil in DNA. Interestingly, the subtle distinction between thymine and 
uracil is a methyl group on the 5-position of the former (Figure 1B). It is believed that this 
refined difference evolved by the more stable nature of thymine and its enhanced base-pairing 
properties. Despite the structural similarity, incorporation of uracil instead of thymine in 
DNA causes mutations and cellular toxicity, both in prokaryotic and eukaryotic organisms 
[29, 30]. For this reason, the cell has developed highly efficient mechanisms to both prevent 
uracil from getting into DNA and to remove uracil from DNA if it is erroneously 
incorporated.  
Since DNA polymerases incorporate dUTP and dTTP with similar efficiency, a high 
dTTP/dUTP ratio is necessary to guarantee thymine over uracil incorporation into DNA [31]. 
This balance is complicated by the fact that de novo thymidine synthesis is dependent on 
dUMP to be methylated to dTMP by the enzyme thymidylate synthase (TS) [23].  If dUMP 
levels accumulate mono- and di-phosphate kinases sequentially phosphorylate dUMP to 
dUTP, rendering the non-canonical deoxynucleotide available for DNA synthesis. 
Mis-incorporation of uracil into DNA is recognized by the BER machinery, leading to 
base-excision by uracil-DNA glycosylases [32, 33].  
In order to prevent accumulation of deoxyuridine triphosphates and mis-incorporation during 
DNA synthesis, deoxyuridine triphosphatase (dUTPase) hydrolyzes dUTP back to dUMP and 
pyrophosphate (Figure 3A) [34]. This reaction not only limits dUTP accumulation, but 
additionally supplies TS with its substrate dUMP, ensuring the availability of the thymidine 
precursor.  
By hydrolyzing dUTP to dUMP dUTPase is considered a main regulator of the uracil pool. 
Accordingly, basically every bacterial, archaeal or eukaryotic genome encodes a protein with 
dUTPase activity, even though they do not exhibit structural homology [28]. Human 
dUTPase is a propeller-shaped homotrimer, with each protomer folding into an eight-stranded 
jelly-roll β barrel (Figure 3B) [35]. The C-terminal β strand is stretched to the adjacent 
domain, tightly locking the molecules. Each enzymatic homotrimer contains three identical 
active sites, which are formed by the interplay of all three subunits (Figure 3B) [35]. High 
specificity for uracil and deoxyribose is reached by a tight hydrogen-bonding network  
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Figure 3: The dUTPase homotrimer hydrolyzes dUTP to dUMP and pyrophosphate. A) dUTP is 
hydrolyzed to dUMP and pyrophosphate (PPi) by the enzymatic activity of dUTPase. B) The human 
dUTPase trimer consists of three identical subunits (blue, red, green), which interconnect to form 
three identical active sites. C) A specific hydrogen bonding network built by all three protomers, 
ensures dUTP selectivity. Graphical depiction adapted from reference [35] (PDB accession code: 
1Q5H).  
 
between dUTP and dUTPase [35]. The active site is capped by the flexible, glycine-rich 
C-terminal tail, which forms specific interactions with the bound dUTP. 
Due to the fact that mitochondria contain a separate genome it is not surprising that both a 
mitochondrial and a nuclear dUTPase isoform exist in humans [36, 37]. The two isoforms are 
encoded by a single gene on chromosome 15. Two different promoters and two distinct 5’ 
exons give rise to the two isoforms, which differ in the N-terminal mitochondrial target 
sequence. In addition, the nuclear isoform features a consensus target sequence for the 
cyclin-dependent protein kinase p34 (cdc2), suggesting cyclin-dependent regulation by 
phosphorylation of Serine 11 [38].  
A 
B 
+ dUTPase 
dUTP dUMP PP
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In healthy cells, expression of the nuclear dUTPase isoform is regulated in a cell 
cycle-dependent manner, both on mRNA and protein level [39-41]. Possible regulatory 
mechanisms for the S-phase specific expression pattern are the consensus E2F binding 
sequence in the putative promoter region and the observed phosphorylation at Serine 11 [32, 
42]. On the contrary, the mitochondrial dUTPase isoform is constitutively expressed, likely 
resulting from the distinct replication pattern of mitochondrial DNA [39].  
In neoplastic tissue, dUTPase expression was found to be deregulated and profoundly 
variable, both in quantity and intracellular localization [40]. Expression of nuclear dUTPase 
did not correlate with the proliferation marker Ki67 in human tumors [40, 41]. The 
intracellular distribution of dUTPase was highly variable, covering solely cytoplasmic, as 
well as exclusively nuclear staining. Moreover, Strahler et al. measured low levels of 
dUTPase in breast, lung and colon cancers and increased expression in neuroblastomas and 
hematopoietic malignancies [43]. Depending on the genetic background of the cell, both 
conditions could be considered beneficial for the tumor. High dUTPase expression could 
protect fast replicating cells from deoxyuridine mis-incorporation-induced toxicity. On the 
other hand, tumors with low dUTPase levels could benefit from non-toxic genetic instability, 
induced by uracil substituted DNA [37].  
In summary, to prevent accumulation of the deoxyuridine pool the hydrolysis of dUTP to 
dUMP by dUTPase is of vital importance for both prokaryotic and eukaryotic organisms [29, 
30].   
 
Deoxycytidine triphosphatase (dCTPase) 
The enzyme deoxycytidine triphosphatase (dCTPase, dCTP pyrophosphatase 1, DCTPP1, 
XTP3-transactivated protein A or XTP3-TPA) has recently been suggested to be involved in 
nuclear and mitochondrial genome integrity, by possessing hydrolase activity with 
deoxycytidine and 5-modified deoxycytidine triphosphate species (Figure 4) [27]. A role for 
dCTPase in carcinogenesis is supported by the finding that overexpression of the enzyme in 
breast, gastric, lung, liver, cervical and esophagus cancer tissue was associated with cancer 
growth and poor clinical prognosis [44-46]. The suggested role of dCTPase in nucleotide 
homeostasis and carcinogenesis makes it of high interest to further characterize the cellular 
function of this all-α NTP pyrophosphatase family member. 
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As the name suggests, dCTP is the preferred canonical substrate for dCTPase (dCTP 
kcat/KM = 119,000 versus 28,000, 25,000 and no detectable activity, for dTTP, dATP and 
dGTP, respectively) [27]. Accordingly, transient depletion of dCTPase resulted in 
accumulation of the intracellular dCTP levels [27]. However, dCTPase knockdown had no 
effect on dTTP levels, even though deamination of dCMP (dUMP) provides the immediate 
precursor for de novo thymidine synthesis (Figure 2) [27]. The slight increase in relative 
dCTP levels associated with dCTPase-depletion, were not found to affect proliferation or 
viability of MRC-5 and HeLa cells, over a seven day period [27]. 
Interestingly, modifications at the 5-position of deoxycytidine, e.g. halogenation to 
5-iodo-dCTP or 5-bromo-dCTP, significantly increased the enzymatic activity in vitro [47, 
48]. Halogenated cytidine species have been observed in chronically inflamed tissue and 
herpes simplex virus (HSV)-infected cells [49]. Salvage of these non-canonical 
(deoxy)cytidine-species could disturb the epigenetic make-up of cells, which has been 
suggested to link inflammation and tumorigenesis [50-52]. The hydrolysis of halogenated 
nucleoside triphosphates by dCTPase could act as a protective mechanism to minimize 
inflammation-induced mutagenesis.  
Besides halogenated species, 5-methyl-dCTP and 5-formyl-dCTP have been identified as 
dCTPase substrates [27, 46]. Whereas 5-methyl-C is a well characterized mediator of 
epigenetic gene silencing, little is known about the recently identified oxidized forms 
5-hydroxymethyl-C, 5-formyl-C and 5-carboxy-C [53-56]. Hydrolysis of 5-methyl-dCTP and 
5-formyl-dCTP by dCTPase could counteract usage of the damaged cytosine-species for 
nuclear and mitochondrial DNA synthesis and thereby preserve epigenome fidelity. Cellular 
data on the importance of dCTPase for epigenetic integrity are limited and contradicting. 
Song et al. demonstrated that dCTPase levels influence global methylation levels and 
associated stemness [46]. On the other hand, Requena et al. found no alterations of 
5-methyl-dC levels in DNA after depletion of dCTPase alone, but after stimulation with 
additional 5-methyl-dC [27].  
In addition, further research is needed to understand the metabolism and the occurrence of 
5-modified deoxycytidine triphosphates. It has been suggested that the substrate specificity of 
deoxycytidine kinase (DCK) and cytidine monophosphate kinase 1 (CMPK1) provides a 
barrier for salvage of 5-hydroxymethyl-dC, 5-formyl-dC and 5-carboxy-dC, limiting the 
formation of their triphosphate derivatives [57].   
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Overall, these findings suggest not only a role for dCTPase in balancing dCTP levels, but also 
in sanitization of 5-modified deoxycytidine analogs, such as halogenated nucleotides during 
inflammation and epigenetically involved 5-methyl-dCTP and 5-formyl-dCTP. By balancing 
and sanitizing the dNTP pool dCTPase activity might play a critical role in maintaining 
nucleotide homeostasis and epigenome fidelity. 
 
 
 
Figure 4: dCTPase hydrolyzes deoxycytidine and 5-modified deoxycytidine triphosphates to the 
corresponding monophosphates and pyrophosphate (PPi).  A) dCTP is converted to dCMP and PPi 
by the activity of dCTPase. B) 5-modifications of deoxycytidine increase the enzymatic activity of 
dCTPase. Substrate examples are: dCTP, 5-methyl-dCTP, 5-formyl-dCTP, 5-iodo-dCTP and 
5-bromo-dCTP.    
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The Nudix hydrolase family 
The nucleoside diphosphate linked to some other moiety, X, (Nudix) hydrolase family 
comprises in humans at least 24 enzymes and 5 pseudogenes, from which various members 
have been linked to nucleotide homeostasis and cell viability [58, 59]. The protein family is 
categorized by their collective 23-amino acid Nudix box motif (Gx5Ex2[UA]xREx2EExGU), 
where “U” is an aliphatic, hydrophobic residue and “x” is any amino acid [59]. While these 
core residues are essential for divalent cation coordination (in most cases Mg
2+
), needed for 
the enzymatic activity, the nucleobase selectivity is achieved by adjacent side chains forming 
the active site [28, 60]. Thus, the highly conserved sequence of the Nudix box leads to similar 
enzymatic activity and the heterogeneity of the active site generates the broad substrate 
specificity within the Nudix superfamily.  
As the name indicates, the Nudix family members hydrolyze nucleoside diphosphates that are 
linked to a diverse array of moieties. Substrates for Nudix enzymes include 
(deoxy)nucleoside tri- and di-phosphates (canonical, alkylated, oxidized and halogenated 
derivatives), dinucleotide coenzymes, nucleoside diphosphate sugars and alcohols, 
dinucleoside polyphosphates (NpnN) and capped RNAs [58]. Due to the substrate diversity, 
Nudix enzymes have been linked to various cellular processes, including  sanitation of 
modified or hazardous materials, balancing the (deoxy)nucleoside triphosphate pool and 
mediating signaling pathways. However, for many Nudix family members, the preferred 
physiological substrate and function remains to be elucidated.  
Several members of the Nudix family were originally classified as MutT Homologs (MTH), 
deriving from the Escherichia coli (E. coli) 8-oxo-dGTP sanitizing enzyme MutT. Even 
though this nomenclature frequently remains, in cases of distinct substrate preference it can 
be misleading and should be revised to the Nudix-classification in these cases [58].   
MutT homolog 1 (MTH1)  
The increased cell growth, metabolic activity and oncogene activation of many cancers often 
create a dysregulated reduction-oxidation (redox) environment [61, 62]. In addition to direct 
damage to the DNA molecule, oxidation of the DNA precursor pool is a major hazard for 
genome integrity. In fact, while the DNA bases are protected by helix formation and the 
nuclear membrane, the free dNTP pool is exposed to a highly reactive environment and 
located physically closer to mitochondria, the main source of ROS [12, 13]. To date, more 
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than 20 oxidatievely damaged base lesions have been identified [63]. Due to its high 
abundance, stability and mutagenicity oxidized guanine (8-oxo-G) is one of the best 
characterized lesions. Guided by base pairing properties 8-oxo-dGTP can be mis-inserted by 
DNA polymerases opposite adenine and cytosine in the coding strand [64]. If these 
substitutions remain undetected and unrepaired by the BER machinery (including the DNA 
glycosylases OGG1 and MUTYH) 8-oxo-G can cause A:T → C:G and G:C → T:A 
transversion mutations [64, 65].  
To prevent oxidative damage to cellular components, including proteins, lipids, DNA and the 
nucleotide pool, cancer cells often adapt by upregulating redox protective mechanisms [66]. 
The high mutagenicity of 8-oxo-dGTP highlights the importance for mechanisms that prevent 
accumulation of this DNA precursor [67]. The MutT Homolog 1 (MTH1 or Nudix-type 1; 
NUDT1) was the first identified human homolog of the E. coli 8-oxo-dGTPase MutT [68-
70]. Upregulation of MTH1 has been observed in many cancer types and is considered as a 
possible protective mechanism to prevent oxidative damage [71-73]. 
In addition to 8-oxo-dGTP, the human MTH1 protein sanitizes the nucleotide pool from the 
oxidized purines 2-OH-dATP, 8-OH-dATP and the corresponding ribonucleotides 
2-OH-ATP, 8-OH-ATP and 8-oxo-GTP [74-76]. By hydrolyzing these oxidatively damaged 
purines, MTH1 prevents their accumulation and hazardous incorporation into DNA and 
RNA. RNA interference-mediated silencing of MTH1 has been shown to result in 
accumulation of 8-oxo-G in DNA, which was associated with increased DNA damage and 
cell death [71, 77-80]. MTH1 knockout mice are fertile and have the same life span as wild 
type mice, but possess an increased risk for spontaneous tumorigenesis. Isolated fibroblasts of 
these mice have been shown to be hypersensitive to H2O2 [81, 82]. Whereas MTH1 has been 
shown to be an important sanitizer of the oxidized nucleotide pool, other consequences of 
MTH1 inhibition are only just now beginning to be uncovered. Besides being DNA building 
blocks, (d)GTP and (d)ATP are involved in various cellular functions, including RNA 
synthesis, metabolism and cell signaling.  Disturbing (d)GTP and (d)ATP homeostasis could 
therefore have additional consequences for cellular integrity.  
High hopes lie on exploiting the function of MTH1 for cancer specific treatment and several 
potent small molecule inhibitors have been presented in the scientific literature [71, 77, 83, 
84]. However, the validity of MTH1’s role in cancer and as a drug target has recently been 
questioned. Several small molecule compounds have been published that inhibit the 
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8-oxo-dGTPase activity of MTH1 in vitro, but do not induce cancer cell death [84-86]. 
Interestingly, these compounds were found to not affect 8-oxo-G levels in DNA, which may 
explain the lack of cellular toxicity (unpublished data) [85]. Whereas additional research is 
needed to clarify the controversy and complexity of MTH1 biology, exploiting the oxidative 
stress levels of cancer remains a promising strategy for anti-cancer therapy. 
NUDT15 and other potential sanitizers of the oxidized nucleotide pool  
The increasing interest to exploit the dysregulated redox environment of cancer cells for 
novel anti-cancer treatments raised the interest for additional sanitizers of the oxidized 
nucleotide pool. Several Nudix family members, including NUDT15 (MTH2), NUDT18 
(MTH3) and NUDT5, have been suggested to function as hydrolases of oxidatively damaged 
nucleotides [87-89].  
The closest MTH1 sequence homolog MutT Homolog 2 (MTH2, Nudix-type 15 or 
NUDT15) has been shown to hydrolyze 8-oxo-dGTP as well as 8-oxo-dGDP to 8-oxo-dGMP 
in vitro [65, 87, 88], although to a considerably lesser extent than MTH1. In line with this, 
overexpression of mouse NUDT15 protein reduced the mutation frequency of E. coli cells 
depleted of the 8-oxo-dGTPase MutT [87]. Furthermore, siRNA-mediated knockdown of 
NUDT15, as well as NUDT5, increased 8-oxo-dGTP-induced A:T → C:G substitution 
mutations on a reporter plasmid transfected into human 293T cells [65].  
Interestingly, NUDT15 was found to physically interact with its C-terminal region to the 
N-terminus of proliferating cell nuclear antigen (PCNA), despite lacking a consensus motif 
for PCNA-binding, like the PIP-box or KA-box motif [90]. The authors suggested that this 
binding stabilizes and protects PCNA from UV-irradiation-induced acetylation and 
degradation by the proteasome. These findings suggest that the 8-oxo-dGTPase activity of 
NUDT15 could be of particular importance during exceptional situations and at distinct 
subcellular locations, as for example the replication fork. To complicate the picture, NUDT15 
has been suggested to possess mRNA decapping activity, both on mono-methylated and 
un-methylated capped RNAs [91, 92].  
Overall, the low enzymatic activity of NUDT15, NUDT18 and NUDT5 with oxidized 
nucleotides raised doubt about the physiological importance of these activities in a cellular 
context. Additional cellular experiments are needed to understand the contribution of these 
hydrolases for sanitation of the oxidized nucleotide pool. In addition, the 8-oxo-(d)GTPase 
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activity of the Nudix family member NUDT17, which structurally clusters together with 
NUDT1, NUDT15 and NUDT18, has received no experimental attention before the start of 
this thesis [88].  
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1.3 Antimetabolites: disrupting nucleotide homeostasis 
Since a balanced and undamaged nucleotide pool is critical for cellular survival, interfering 
with nucleotide homeostasis has been a long exploited strategy to treat cancer. Synthetic 
nucleobase- and nucleoside-analogs (antimetabolites) have been developed that resemble 
endogenous metabolites and thereby interfere with various cellular processes. Besides for 
cancer therapy, nucleobase- and nucleoside-analogs are commonly used as anti-viral agents 
and as immunosuppressants [3]. 
Upon treatment, nucleobase- and nucleoside-analogs undergo the same metabolic processing 
as endogenous nucleotides. Cellular uptake, of the often hydrophilic compounds, is mediated 
by specific nucleoside transporters, including equilibrative uniporters, antiporters, 
concentrative transporters and ABC transporters [93-96]. Inside the cell, the analogs are 
substrates for the endogenous purine and pyrimidine salvage pathways. These involve various 
nucleoside kinases and nucleoside monophosphate kinases that lead to phosphorylation of the 
antimetabolites [3]. Subsequent metabolic activity of a nucleoside diphosphate kinase, 
creatine kinase or 3-phosphoglycerate kinase leads to the formation of nucleoside 
triphosphate analogs [3]. The phosphorylated non-canonical derivatives compete with 
physiological nucleotides and thereby disturb various cellular processes, including nucleotide 
homeostasis, DNA and RNA synthesis, enzyme function, signaling and metabolism. Due to 
this multifaceted attack, the physiological consequences of nucleobase- and 
nucleoside-analogs are often complex and dependent on the molecular background of the 
cell.  
In this section, the metabolism and molecular mode of action for the antimetabolites 5-FU, 
decitabine and 6-TG will be discussed in more detail. A summary of their drug class, active 
metabolites, primary target(s) and molecular mechanism can be found in Figure 5. 
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Structure 
 
   
Therapeutic agent 5-fluorouracil decitabine 6-thioguanine 
Abbreviation 5-FU 5-aza-dC 6-TG 
Drug class fluoropyrimidine cytidine analog thiopurine 
Active metabolite 5-fluoro-dUMP 
5-fluoro-dUTP 5-aza-dCTP 
6-thio-dGTP 
6-thio-GTP 
Primary target(s) 
and mechanism 
 
TS inhibition, 
nucleotide 
imbalance, 
DNA and RNA 
mis-incorporation, 
DNA damage 
DNA incorporation, 
hypomethylation, 
DNMT1 trapping, 
DNA damage 
DNA and RNA 
mis-incorporation, 
DNA damage 
 
Figure 5: Nucleobase- and nucleoside-analogs discussed in this thesis. 
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Fluoropyrimidines 
Fluoropyrimidines belong to the oldest and most-effective chemotherapeutics that are used 
today. Even though the precise mechanism of action was not known during the development 
of the first fluoropyrimidine in 1957 the invention is a great example of rational drug 
discovery [4]. Heidelberger et al. based the synthesis of fluorinated pyrimidine analogs on 
four observed phenomena 1) replacing molecular hydrogen by fluorine leads to profound 
alterations in biological function, 2) nucleic acid precursor-analogs have anti-tumor activity, 
3) rat hepatomas mis-incorporate uracil into DNA to a greater extent than healthy cells, 
4) uracil-based synthetic compounds possess anti-tumor activity [97-101]. Today, almost 60 
years after the first application, 5-FU remains a cornerstone in the treatment regimen against 
a wide array of solid tumors, including colorectal cancer, pancreas, breast, gastric, and 
ovarian cancers [101]. However, despite improved treatment regimens, side effects and drug 
resistance remain major drawbacks of fluoropyrimidine therapy.   
Mode of action of fluoropyrimidines 
Even though 5-FU belongs to the oldest chemotherapeutics used today the exact mechanism 
of toxicity remains debated. 5-FU treatment results in a multifaceted phenotype due to its 
intertwined mode of action involving 1) inhibition of the enzyme thymidylate synthase (TS) 
and subsequent nucleotide pool imbalance 2) mis-incorporation of dUTP and 5-fluoro-dUTP 
into DNA and 3) disturbance of RNA synthesis by 5-fluoro-UTP.   
One of the main consequences of 5-FU treatment is inhibition of TS, an essential enzyme for 
thymidine production. TS catalyzes the reductive methylation of dUMP to dTMP, utilizing 
5,10-methylenetetrahydrofolate (CH2THF) as the methyl donor (Figure 6) [102]. The 
substrate dUMP can originate from two main sources: deamination of dCMP by 
deoxycytidylate deaminase (DCD) and reduction of UDP by RNR [32]. The oxidized 
by-product dihydrofolate (DHF) is recycled by the combined action of dihydrofolate 
reductase (DHFR) and serine hydroxymethyltransferase (SHMT). Since the TS reaction 
product dTMP is the sole source of de novo thymidine, TS is considered one of the few 
metabolic bottlenecks in the biosynthesis of DNA precursors [101]. The necessity of 
CH2THF as a cofactor highlights the importance of adequate folate metabolism for thymidine 
production. 
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Figure 6: Metabolism and mode of action of 5-fluorouracil (5-FU). The non-canonical base 5-FU is 
converted by uracil metabolizing enzymes into the main active components 5-fluoro-dUMP, 
5-fluoro-UTP and 5-fluoro-dUTP. Whereas 5-fluoro-dUMP inhibits the enzyme thymidylate synthase 
(TS), inducing dNTP pool imbalance, 5-fluoro-UTP and 5-fluoro-dUTP get mis-incorporated into 
RNA and DNA, respectively. (1) thymidine phosphorylase; TP, (2) thymidine kinase; TK, (3) 
pyrimidine monophosphate kinase; NMPK, (4) pyrimidine diphosphate kinase; NDPK,  (5) 
ribonucleoside diphosphate reductase; RNR, (6) uridine phosphorylase; UP, (7) uridine kinase; UK, 
(8) deoxythymidine monophosphate kinase; dTMPK, (9) dihydrofolate reductase; DHFR, (10) serine 
hydroxymethyltransferase; SHMT1, (11) methylentetrahydrofolate-reductase; MTHFR. Graphical 
depiction adapted from Reference [101]. 
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The presence of two distinct, cofactor and substrate, binding pockets provides the possibility 
to impede the enzymatic function of TS with two structurally distinct classes of 
antimetabolites: antipyrimidines and antifolates.  Anti-pyrimidines that inhibit TS function 
include among others the fluoropyrimidines 5-FU, 5-fluoro-deoxyuridine (FdUrd) and the 
pro-drug capecitabine. The therapeutic fluoropyrimidine bases are metabolized to the main 
effector metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (5-fluoro-dUMP) by 
enzymes of the pyrimidine nucleotide synthesis pathway. 5-fluoro-dUMP competes with the 
natural substrate dUMP for covalent binding to the substrate pocket of TS and thereby 
inhibits the enzyme [103, 104]. Antifolates, on the other hand, can exhibit TS inhibition 
either directly by binding to the enzymatic co-factor pocket (e.g. by ZD1694 and ZD9331) or 
indirectly through depletion of the CH2THF pool as a consequence of DHFR inhibition (e.g. 
by methotrexate and metoprine) [101].  
Targeting TS, directly or indirectly, leads to depletion of the product dTMP while the 
substrate dUMP accumulates before the metabolic blockage. It was originally assumed that 
the extreme depletion of dTMP and subsequent shortage of the DNA precursor dTTP are the 
main causes of the observed DNA synthesis arrest and cytotoxicity; a condition termed 
“thymineless death” [105]. However, it has been suggested that, besides dTTP deficiency, 
expansion of the dUTP pool and subsequent uracil mis-incorporation into DNA are important 
components of TS-induced toxicity [106]. Moreover, treatment with fluoropyrimidines leads 
to accumulation of 5-fluoro-dUTP, which further raises the uracil pool. Since DNA 
polymerases incorporate dTTP, dUTP and 5-fluoro-dUTP with similar efficacy, the 
nucleotide imbalance can result in DNA mis-incorporation of uracil and fluoro-uracil [31]. 
These DNA lesions are subject for the base excision repair (BER) and mis-match repair 
(MMR) machinery, which try to resolve the DNA damage. However, if the nucleotide 
imbalance persists, futile excision and re-incorporation of erroneous (fluoro-)uracil creates 
numerous abasic sites, single- and double-strand breaks [31, 106-111]. Activation of 
homologous recombination (HR) is a last attempt to repair these lesion and prevent cellular 
death [112].   
Various research groups have demonstrated the importance of BER and HR for 
fluoropyrimidine toxicity, by depletion of major repair proteins [112-115]. A more discrepant 
picture has developed over the importance of the different DNA-glycosylases for uracil and 
5-FU excision and fluoropyrimidine-induced cell death, resulting from the use of different 
model systems and TS-inhibitors. It has been shown that knockout of the major 
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replication-associated uracil-DNA glycosylase, UNG, in mouse embryonic fibroblasts does 
not affect the sensitivity to TS inhibitors [116]. In line with this, FdUrd or 5-FU efficacy was 
not altered by expression of Ugi, a protein inhibitor of UNG family members [117]. 
However, higher vertebrates, but not lower eukaryotes such as Saccharomyces cerevisiae, 
express a second glycosylase named SMUG1. Qian An et al. suggests that SMUG1 
expression, contrary to UNG, influences 5-FU toxicity through excision of 5-FU lesions from 
DNA [118]. This study was disputed by a study from Pettersen et al. who showed that even 
though UNG-initiated BER is mainly responsible for repairing 5-FU in DNA, this mechanism 
does not contribute to cytotoxicity of 5-FU, but of FdUrd [119]. In addition, the activity of 
the thymine DNA glycosylase (TDG) has been linked to 5-FU-induced DNA strand breaks, 
cell cycle alterations and DNA damage [110].  
Besides the incorporation of 5-fluoro-dUTP into DNA several studies have suggested that 
mis-incorporation of 5-fluoro-UTP into RNA contributes to fluoropyrimidine-induced 
toxicity and might even be the prevalent cause [119-124]. RNA mis-incorporation of the 
fluoro-substituted nucleotide has been shown to disturb among others: maturation of 
ribosomal RNA, activity of small nuclear RNA-protein complexes, RNA exosome function 
and modification of transfer RNAs [125-129]. Successful rescue experiments with uridine 
highlight the importance of RNA-disturbances for TS inhibitor-induced toxicity [120, 130, 
131].  
These data demonstrate that the working mechanism of fluoropyrimidines is complex and the 
exact cause of toxicity not fully understood. Generally, one can say that the 5-FU-induced 
toxicity results from a complex molecular interplay involving: dTTP depletion, accumulation 
and incorporation of (5-fluoro-) dUTP into DNA, as well as disturbance of RNA synthesis by 
5-fluoro-UTP. The contribution of each part to cell toxicity is most likely dependent on the 
type of TS-inhibitor and the genetic make-up of the cell.  
In the clinic, administration of 5-FU as a single agent achieves response rates of only ~10% 
[132]. During 6 decades of clinical application various combination therapies and treatment 
regimens have been established to improve the therapeutic success. Combining 5-FU with 
modulating agents like leucovorin, levamisole or methotrexate or administration by 
continuous venous infusion increased the objective response rate in patients [133]. However, 
response rates merely reach 50% and drug resistance is an inevitable problem.  
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Intrinsic or acquired drug resistance can result from alterations in each step of the molecular 
mechanism, including cellular uptake and efflux, drug metabolism and catabolism, target 
expression and alterations in the cellular response. Several causes for 5-FU resistance have 
been described, among others upregulation of TS [134, 135], Bcl-2 [136], Bcl-XL [136, 137], 
and Mcl-1 [138], and methylation of the MLH1 gene [139], highlighting the importance of 
DNA repair pathways for toxicity. In addition, expression of the nucleotide hydrolase 
dUTPase has been found to negatively correlate with 5-FU treatment success [40].  
Link between dUTPase and 5-fluorouracil metabolism 
The physiological function of dUTPase is to protect cells from dUTP pool expansion and 
thereby prevent toxic consequences of uracil mis-incorporation into DNA (Figure 6) [140]. 
However, from a treatment perspective dUTPase activity could hamper accumulation of 
dUTP and the active 5-FU metabolite 5-fluoro-dUTP and thereby reduce intended 
cytotoxicity.  
Evidence for an influential role of dUTPase in TS inhibitor-induced toxicity has been 
presented in prokaryotic and eukaryotic systems. In E. coli, ectopic overexpression of 
dUTPase caused resistance to FdUrd-induced DNA strand breaks and toxicity [141]. In the 
human colorectal adenocarcinoma cell line HT29 overexpression of both human and E. coli 
dUTPase reduced FdUrd-associated dUTP levels, DNA damage and cytotoxicity [141]. 
Interestingly, a study by Leslie et al. suggested that the observed protective effects of 
dUTPase overexpression on TS-inhibitor toxicity were a time dependent phenomenon [142]. 
Whereas dUTPase overexpressing cells were less sensitive in the first 24 hours of the 
treatment, similar toxicity was demonstrated after 48 hours. In addition, the influence of 
dUTPase depletion on TS inhibitor effectiveness has been validated in several studies using 
siRNA-mediated protein knockdown. Overall, depletion of dUTPase negatively reflected the 
phenotype observed after overexpression of the nucleotide triphosphatase. If TS-targeted 
therapies were combined with dUTPase depletion intracellular dUTP pools were found to be 
increased, which potentiated DNA damage and cell death. This has been studied in non-small 
cell lung cancer (A549, H358, H1299, and H460), colon cancer (SW620), cervix (HeLa) and 
breast cancer (MCF-7) cell lines [143-145].    
All these studies confirm that overexpression and knockdown of dUTPase significantly 
influence the efficacy of TS inhibitors. In addition, endogenous dUTPase levels were found 
to be predictive for response to TS inhibitors in various cancer cell lines [146, 147]. In line 
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with this, in colorectal cancer patients treated with 5-FU, high intra-tumoral dUTPase 
expression was found to be significantly associated with reduced treatment response, shorter 
time to progression and shorter survival [40]. Furthermore, primary tumors with metastasis 
were found to express higher levels of dUTPase, compared to non-metastatic tumors [41, 
148]. Due to these clinical observations, dUTPase was suggested as a biomarker for both 
prognostic TS inhibitor effectiveness and metastatic potential.  
 
Decitabine 
Whereas protein structure and function is determined by the genetic sequence, the expression 
level is influenced among others by epigenetic alterations, including DNA methylation and 
histone modifications [149]. Methylation of cytosine residues in CpG promoter islands 
induces gene silencing through chromosome condensation [150, 151]. This epigenetic 
information is induced and maintained by the methylation activity of the protein family of 
DNA methyltransferases (DNMTs) [152]. During a post-replicative process DNMTs 
covalently bind to the cytosine ring and subsequently transfer a methyl group from 
S-adenosyl-L-methionine (SAM) to the 5-carbon of the base [151]. Fulfillment of the 
complete reaction is necessary to release the methyltransferase from the DNA strand. While 
in healthy cells 60-90% of cytosine residues in CpG sequences are methylated, cancers often 
utilize an abnormal methylation status to silence critical tumor suppressor genes, like Rb1, 
VHL or hMLH1 [153-156]. Reversing epigenetic alterations is a promising strategy to treat 
cancer, since the underlying genetic information remains intact.  
In 1964, Pliml and Sorm synthesized decitabine (5-aza-2’-deoxycytidine or 5-aza-dC), a 
cytosine-analog in which nitrogen (N) substitutes the 5-carbon (Figure 7) [5]. Following 
intracellular uptake, the synthetic base gets phosphorylated by deoxycytidine kinases forming 
5-aza-dCTP, which gets inserted by DNA polymerases into nascent DNA [93, 157, 158]. The 
paired 5-aza-C:G dinucleotide is recognized as endogenous CpG sequence by DNMT. A 
subsequent nucleophilic attack forms a covalent bond between the 6-carbon of the base and 
the methyltransferase [159-161]. The nitrogen at the 5-position of the analog prevents the 
beta-elimination normally executed by the 5-carbon of cytosine, covalently trapping the 
DNMT molecule to the DNA [161].  
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Figure 7: DNMT1 activity and mode of action of the deoxycytidine analog decitabine (5-aza-dC). 
To maintain the epigenetic signature DNMTs covalently bind cytosine and transfer a methyl-group 
from SAM to the 5-carbon of the base (left panel).The synthetic cytosine analog 5-aza-dC enters the 
cell and gets phosphorylated by (1) deoxycytidine kinase (2) deoxycytidine monophosphate kinase and 
(3) nucleoside diphosphate kinase. If accumulated the triphosphate species can get mis-incorporated 
into DNA by DNA polymerases. In an attempt to methylate the cytosine analog DNMT covalently 
binds the synthetic base. Due to the 5-nitrogen DNMTs cannot proceed with the methylation reaction, 
which traps the enzyme to the base. Whereas low levels of decitabine (middle panel) result in 
hypomethylation and gene reactivation, high levels (right panel) cause DNA damage and DNA 
synthesis arrest. Graphical depiction adopted from [151].     
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Dependent on the amount of incorporated 5-aza-dC into DNA two distinct physiological 
outcomes are the consequence. In the case of low 5-aza-dC levels, DNMTs are degraded, 
resulting in demethylation and restoration of gene expression [162]. On the other hand, 
increased levels of 5-aza-dC cause disturbances in DNA synthesis and cell cycle progression 
which, if accumulated, induce DNA damage and cytotoxicity [163, 164]. Decitabine has been 
proven effective in the treatment against hematologic malignancies, including acute myeloid 
leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome 
(MDS). However, the therapeutic success is limited to a response rate of only 50% and 
cancer relapse is a common problem [165, 166].   
Recently, the activity of the nucleotide hydrolases dCTPase and dUTPase has been suggested 
to influence decitabine efficacy [48]. Knowing from previous studies that dCTPase 
hydrolyzes 5-modified deoxycytidine species Requena et al. demonstrated activity with the 
active decitabine metabolite 5-aza-dCTP [27]. In line with this, dCTPase depletion 
potentiated decitabine-induced global DNA demethylation and cell death. Interestingly, the 
authors of this study suggest, that besides 5-aza-dCTP incorporation, the metabolism to 
5-aza-dUMP and subsequent TS inhibition is a component of the mode of action of 
decitabine. They support this hypothesis by dUTPase and dCTPase knockdown experiments, 
that demonstrated increased levels of uracil mis-incorporation and double-strand break 
formation when dUTPase and dCTPase were depleted during decitabine treatment. 
Decitabine treatment additionally up-regulated several enzymes involved in pyrimidine 
metabolism, including dCTPase and dUTPase [48]. This study suggests that targeting 
dUTPase and dCTPase activity could be a novel strategy to improve the treatment response to 
decitabine.  
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Thiopurines  
Historically, the development of medicine was based on a trial-and-error process, which was 
often subjected to chance. During the 1940’s George Hitchings and Gertrude Elion 
questioned this traditional way of drug development and rather believed in a process today 
known as “rational drug design”. At the time, the success of sulfur containing drugs raised 
their attention and led them to the hypothesis that this principal could be applied to interfere 
with cellular proliferation. Based on this assumption they synthesized the first synthetic 
guanine analog, in which they substituted the 6-oxygen of the purine ring with sulfur: 6-TG 
was discovered [48]. In addition, the development of the thiopurine pro-drugs 
6-mercaptopurine (6-MP) and azathioprine (AZA-T) can be accredited to the research of 
Hitchings and Elion, who in 1988 received the Nobel Prize in Physiology or Medicine for 
their pioneering work on the "important principles for drug treatment". Still today, 6-TG, 
6-MP and AZA-T are commonly used anti-cancer drugs, which are additionally repurposed 
as anti-inflammatory and immunosuppressive agents. However, treatment response to 
thiopurines is highly variable, reaching from intrinsic or acquired drug resistance to cases of 
hypersensitivity.  
Metabolism of thiopurines 
6-TG, 6-MP and AZA-T are pro-drugs, which need to undergo extensive metabolism to exert 
their cytotoxic effects (Figure 8) [167, 168]. AZA-T is the most distinct pro-drug, which 
through a non-enzymatic reaction is converted to 6-MP and an imidazole group. Both 6-TG 
and 6-MP are transported into the cell where they enter the purine salvage pathway. In a first 
step, hypoxanthine phosphoribosyltransferase (HPRT) adds ribose-5-phosphate to the base 
and thereby creates the nucleoside monophosphates 6-thio-IMP and 6-thio-GMP. Additional 
metabolism by inosine monophosphate dehydrogenase (IMPDH) and guanine 
monophosphate synthetase (GMPS) converts 6-thio-IMP to 6-thio-GMP. The sequential 
activity of deoxynucleotide kinases and reductases creates the active metabolites 6-thio-dGTP 
and 6-thio-GTP, which are accountable for the majority of cytotoxic effects of this drug-class.  
The efficiency of thiopurine activity is not only determined by conversion of the pro-drugs to 
the active metabolites, but also by competing reactions that inactivate various derivatives 
[167, 168]. Thiopurine S-methyltransferase (TPMT) methylates 6-MP, 6-TG, as well as their 
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Figure 8: Metabolism and mode of action of thiopurines. AZA-T, 6-MP and 6-TG are metabolized to 
the active derivatives 6-thio-dGTP and 6-thio-GTP, which are incorporated into DNA and RNA 
respectively. (1) hypoxanthine–guanine phosphoribosyltransferase; HPRT, (2) inosine 
monophosphate dehydrogenase; IMPDH, (3) guanine monophosphate synthetase; GMPS, (4) 
monophosphate kinase; NMPK, (5) diphosphate kinase; NDPK, (6) ribonucleoside reductase; RNR, 
(7) TPMT: thiopurine S-methyltransferase, (8) guanine deaminase: GAH,  (9) xanthine oxidase: XO, 
(10) aldehyde oxidase: AO.  Abbreviations: AZA-T: azathioprine, 6-MP: 6-mercaptopurine, 6-TG: 
6-thioguanine. Graphical depiction adapted from references [167, 168]. 
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corresponding nucleoside monophosphates 6-thio-IMP and 6-thio-GMP and thereby prevents 
their progression in the biosynthetic pathway. Besides detoxification of AZA-T, 6-MP and 
6-TG by TPMT, xanthine oxidase (XO) and aldehyde oxidase (AO) contribute to the 
catabolism of the thiopurines [167, 168]. 
Mechanism of thiopurine-induced toxicity 
The mode of action of thiopurines is complex and even after six decades of clinical 
application not completely understood. The main active metabolites of all three thiopurine 
pro-drugs are 6-thio-dGTP and 6-thio-GTP (Figure 8).  By the close resemblance to dGTP 
and GTP these synthetic analogs interfere with nucleotide metabolism, as well as DNA and 
RNA synthesis.  
With a similar Km to unmodified dGTP DNA polymerases incorporate 6-thio-dGTP into 
DNA, replacing between 0.01 and 0.1% of canonical guanine with the sulfur containing 
analog (Figure 9) [169-171]. However, the presence of 6-TG in DNA is neither particularly 
toxic nor mutagenic [167]. 6-TG incorporated into DNA is non-enzymatically methylated, 
most likely by SAM, creating 6-methylthio-G. During the next round of replication, the 
non-canonical base ambiguously pairs with cytosine and thymine [172]. These mis-pairs 
essentially activate the MMR machinery, which attempts to find a correct daughter-strand 
partner for the 6-methylthio-G in the template DNA strand [173, 174]. However, since the 
erroneous base is present in the template DNA strand, processing of this mis-pair is inevitably 
futile [15]. Subsequently, the DNA damage and the MMR machinery trigger checkpoint 
activation, which over the ATR/CHK1 axes results in a strong G2 cell cycle arrest [175-177]. 
Since the mis-incorporation of thiopurines is usually unproblematic until the second round of 
replication, cytotoxicity often does not manifest until day two or three of drug treatment. 
Eventually, too high levels of incorporated 6-thio-dGTP and resulting futile cycles of DNA 
repair induce cellular death.  
Besides incorporation of 6-thio-dGTP into DNA, accumulating evidence has been presented 
that incorporation of the ribonucleotide 6-thio-GTP into newly synthesized RNA is a 
contributing component of thiopurine-induced toxicity [178, 179]. In addition, the 6-MP and 
AZA-T derivative 6-methylthio-IMP has been shown to inhibit de novo purine biosynthesis, 
by inhibition of the enzyme phosphoribosylpyrophosphate amidotransferase (PPAT) [180].  
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It is less well understood how thioguanine species influence the activity of GTP-utilizing 
enzymes, e.g. GTPases. Evidence has been presented, that the immunosuppressive effects of 
6-TG are caused through 6-thio-GTP-induced inhibition of Rac1 (a GTPase), which induces 
T-cell apoptosis [181, 182]. Overall, the exact contribution of these mechanisms to the 
pharmacological effects of thiopurines is poorly understood and clearly dependent on the 
genetic make-up of the cell [183, 184].  
 
        
 
Figure 9: Mechanism of cell toxicity induced by incorporation of 6-thio-dGTP into DNA. In the 
first round of replication DNA polymerases mis-incorporate 6-thio-dGTP, which gets methylated by 
SAM. During the second round of replication, 6-methylthio-G (depicted as G-SM) pairs preferentially 
with cytosine or thymine. The presence of 6-methylthio-G in the template strand is recognized by the 
MMR machinery (involving the dimer MUTSα (MSH2/MSH6), MLH1 and PMS2), but inevitable futile 
repair leads to accumulation of abasic sites that, if accumulated, cause cell death.  
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Link between NUDT15 and thiopurine treatment 
Clinically, sensitivity to all three thiopurine drugs is highly variable, making it necessary to 
carefully monitor treatment effects and adapt the dosing regimen. In an attempt to understand 
this deviation and to prevent over-dose-induced side effects, several pharmacogenetic studies 
have been performed to link genetic alterations to treatment sensitivity. During these studies 
single nucleotide polymorphisms in the TPMT gene, which cause enzymatic inactivity, have 
been identified as major risk factor for thiopurine hypersensitivity [185-188]. In fact, it has 
been advised by the FDA to screen for TPMT inactivating mutations prior to thiopurine 
therapy to be able to adjust the treatment dose and prevent side-effects, such as leukopenia 
and hair loss. Even though pre-treatment screenings for TPMT mutations has been beneficial, 
a high number of hypersensitive cases cannot be explained by this mechanism. This 
observation has been especially prevalent in the Asian population, where TPMT mutations 
are less common [189-192]. These patients with thiopurine hypersensitivity evoked the need 
for additional research, to explain and prevent the observed side-effects in these patients.  
Recent pharmacogenetic screens have identified a link between thiopurine hypersensitivity 
and the NUDT15 variant R139C. Both in patients with inflammatory bowel disease (IBD) 
[190, 193, 194] and childhood leukemia [195-201] the NUDT15 genotype significantly 
influenced the treatment sensitivity to thiopurines. During all these studies mutations in locus 
rs116855232, resulting in an arginine (Arg; R) to cysteine (Cys; C) substitution at position 
139 of NUDT15, were a risk factor for thiopurine hypersensitivity. The described NUDT15 
variants were most common in East Asians, as well as Hispanics, but rare in Europeans and 
were not detected in African patients [195]. These studies suggested a first link between the 
Nudix enzyme NUDT15 and thiopurine treatment sensitivity.   
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PRESENT INVESTIGATION 
2.1 Objective of this work 
The aim of this study was to validate the hydrolases dUTPase, dCTPase and NUDT15 as 
drug targets to disturb nucleotide homeostasis and cellular integrity, both as mono-therapy 
and in the context of antimetabolite treatment. The following questions were addressed:  
Paper I 
- How does 5-FU treatment affect DNA replication? 
- How does dUTPase inhibition influence the 5-FU-induced phenotype? 
- Is inhibition of dUTPase a promising strategy to increase 5-FU sensitivity? 
Paper II 
- What are the biochemical properties of the dCTPase inhibitor TH1217? 
- What is the cellular phenotype evoked by pharmacological inhibition of dCTPase? 
- Is inhibition of dCTPase a promising strategy to increase decitabine sensitivity? 
Paper III 
- Do the Nudix enzymes NUDT15, NUDT17 and NUDT18 possess enzymatic activity 
with 8-oxo-(d)GTP or 2-OH-(d)ATP? 
- Does NUDT15 depletion affect incorporation of 8-oxo-dGTP into DNA, DNA 
integrity and cancer cell survival?  
- What substrates are hydrolyzed by NUDT15? 
Paper IV 
- Does NUDT15 show enzymatic activity and preference towards 6-thio-(d)GTP? 
- What causes thiopurine hypersensitivity in patients with the NUDT15 mutations 
leading to expression of the variant R139C? 
- Do the biochemical and biophysical properties of NUDT15 R139C differ from the 
wild type protein? 
- Does depletion of NUDT15 affect sensitivity to 6-TG?  
Paper V 
- Is NUDT15 a possible target to increase thiopurine sensitivity of leukemia cells? 
- Can we develop potent and selective small molecule inhibitors against NUDT15? 
- Do NUDT15 inhibitors increase thiopurine sensitivity of leukemia cells? 
- What is the mechanism of action of the NUDT15 inhibitor and thiopurine 
combination-treatment? 
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2.2 Research design  
To investigate the importance of dUTPase, dCTPase and NUDT15 in nucleotide homeostasis 
and to validate these (d)NTPases as possible therapeutic targets to increase antimetabolite 
efficacy we used the following study design. 
1. In vitro assessment of substrate specificity  
2. Characterization of cellular phenotypes induced by protein knockdown  
3. Validation of knockdown-induced antimetabolite sensitization  
4. Development of small molecule inhibitors against the (d)NTPases 
5. Characterization of the molecular mechanisms of action underlying the co-treatment 
strategies  
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2.3 Results 
Paper I: dUTPase inhibition augments replication defects of 5-fluorouracil 
TS-inhibitors, including fluoropyrimidines and antifolates, remain a medication of choice in 
the treatment regimens against a variety of solid tumors. However, despite six decades of 
clinical application the exact working mechanism is still debated. The high incidence of 
intrinsic and acquired drug resistance highlights the necessity to fully understand the mode of 
action of TS-directed chemotherapies. Accumulating evidence points to the fact that dUTPase 
activity is an important factor influencing the efficacy of TS inhibitors. By hydrolyzing dUTP 
and 5-fluoro-dUTP to the corresponding monophosphate, dUTPase activity could 
significantly hamper the potency of TS inhibitors (Figure 10A).  
In this study, we unraveled DNA replication defects evoked by 5-FU treatment and assessed 
the role of dUTPase activity for treatment sensitivity. We showed, by extensive cellular 
experiments, that 5-FU treatment decreases replication fork progression and this leads to 
accumulation of cells in S-phase, DNA damage and eventually cell death (Figure 10B-D). 
These effects could be amplified by either depletion of dUTPase protein or inhibition of 
dUTPase activity with small molecule inhibitors. We demonstrated that dUTPase inhibition 
alone does not cause replication or viability defects, but significantly potentiates the cellular 
effect of 5-FU therapy. The influence of dUTPase activity on 5-FU-sensitivity underlines the 
importance of 5-fluoro-dUTP and dUTP accumulation and mis-incorporation into DNA for 
5-FU-induced cytotoxicity.  
With this study, we not only extended the current knowledge about the 5-FU mechanism of 
action, but we also contributed to the characterization of small molecule dUTPase inhibitors 
[202].  
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Figure 10: Main results of Paper I “dUTPase inhibition augments replication defects of 
5-fluorouracil”. A) dUTPase activity hampers 5-FU toxicity by hydrolyzing endogenous dUTP and 
the active 5-FU derivative 5-fluoro-dUTP. B) dUTPase inhibition sensitized colorectal cancer cells to 
5-FU treatment. C) Inhibition of dUTPase potentiated the replication defects of 5-FU, as analyzed by 
measuring EdU incorporation by FACS. D) 5-FU treatment reduced the speed of single replication 
forks, which was augmented when dUTPase was inhibited.  
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Paper II: TH1217, a chemical probe to explore dCTPase pharmacology 
Increasing evidence has been presented that the fairly uncharacterized dCTPase enzyme is, 
through its hydrolyzing activity with deoxycytidine and 5-modified deoxycytidine 
triphosphates, involved in deoxycytidine homeostasis and carcinogenesis (Figure 11A). 
Here, we characterized the small molecule dCTPase inhibitor TH1217 by various 
biochemical, biophysical and cellular assays and demonstrate its value for investigating 
dCTPase biology in vivo (Figure 11B). 
We validated how TH1217 binds to the active site of dCTPase by solving the co-crystal 
structure and confirmed target engagement inside cancer cells by assessing thermal and 
proteolytic degradation. Furthermore, we demonstrated that TH1217 displays exquisite 
selectivity over related hydrolases and a wide panel of relevant pharmacological targets. 
In a cellular setting, inhibition of dCTPase by TH1217 led to an increase of intracellular 
dCTP levels, supporting “effect-through-target”. Short-term inhibition of dCTPase did not 
affect replication speed or cellular survival of HL-60 cells (Figure 11C-D). However, 
chronic exposure (15 days) of HL-60, DOHH-2 and WILL-2 cells to sub-micromolar 
concentrations of TH1217 impaired cell proliferation (Figure 11E). This was not a result of 
changes in the global methylation status, either after TH1217 treatment or dCTPase protein 
depletion, despite substrate preference of dCTPase towards 5-methyl-dCTP.  
In addition, we demonstrated that the activity of dCTPase with the active decitabine 
metabolite 5-aza-dCTP counteracts the treatment efficacy in AML cells. Inhibition of 
dCTPase by TH1217 potentiated the cellular effects of decitabine treatment in AML cells, 
which was supported by knockdown experiments. TH1217 treatment increased 
decitabine-induced accumulation of DNMT1 crosslinking to chromatin, augmented DNA and 
cell death.   
Overall, we demonstrated that TH1217 is a valuable tool compound to unravel the cellular 
function of dCTPase both, in endogenous nucleotide homeostasis and in the context of 
pharmacological intervention with deoxycytidine analogs.  
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Figure 11: Main results of Paper II “TH1217, a chemical probe to explore dCTPase 
pharmacology”. A) dCTPase is involved in homeostasis of the canonical and non-canonical 
deoxycytidine pool by hydrolyzing the triphosphate to the monophosphate species. B) Chemical 
structure of TH1217 C) TH1217 did not influence replication speed, assessed by BrdU incorporation. 
D) Speed of single replication forks was not influenced by dCTPase inhibition. E) Chronic exposure to 
TH1217 influenced cellular proliferation. 
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Paper III: Crystal structure, biochemical and cellular activities demonstrate separate 
functions of MTH1 and MTH2 
Many cancer cells acquire a deregulated redox environment that causes oxidative damage to 
cellular components, including the free dNTP pool. Exploiting this phenotype by targeting 
sanitizers of the nucleotide pool is a novel strategy to induce cancer cell-specific toxicity. 
Here, we assessed the activity of the Nudix enzymes NUDT15 (MTH2), NUDT17 and 
NUDT18 with oxidized guanine and adenine species, to validate their role as sanitizers of the 
oxidized nucleotide pool. 
We demonstrated that, of the tested Nudix enzymes, NUDT15 possesses the second highest 
8-oxo-(d)GTPase activity, after MTH1 (Figure 12A). To characterize this activity in more 
detail we performed a thorough kinetic comparison of MTH1 and NUDT15 with canonical 
and oxidized (d)GTP. Whereas MTH1 had a 40 times higher kcat/KM for 8-oxo-dGTP 
compared to dGTP, NUDT15 displayed a 9 times higher kcat/KM for dGTP compared to 
8-oxo-dGTP (Figure 12B).  
To understand the different substrate specificity of these two sequence homologs, we 
determined the first NUDT15 crystal structure. Noticeably, even though MTH1 and 
NUDT15 share an overall similar fold, a shift in the NUDT15 α2 helix results in a distinct 
substrate binding pocket (Figure 12C). Whereas MTH1 is able to form a tight hydrogen 
bonding network with 8-oxo-dGTP involving Asp119 and Asp120, NUDT15 lacks residues 
with hydrogen bonding abilities at these positions (Figure 12D). As such, NUDT15 is 
unable to potently bind 8-oxo-dGTP.  
Especially in a biological setting, where only a fraction of the total dGTP pool is oxidized, the 
importance of NUDT15 for 8-oxo-(d)GTP sanitization is questionable [67]. In order to 
validate the physiological importance of NUDT15 activity, we analyzed the phenotype 
evoked by NUDT15 and MTH1 protein depletion. As described previously, MTH1 
knockdown increased the 8-oxo-dG level in DNA, leading to DNA damage and cell death 
(Figure 12E-F). In contrast, depletion of NUDT15 had no effect on these parameters. 
Simultaneous knockdown of both, MTH1 and NUDT15, did not reinforce the phenotype 
induced by MTH1 depletion.  
Altogether, our data suggest that NUDT15 has negligible activity towards 8-oxo-(d)GTP and 
is not a biologically relevant sanitizer of the oxidized dNTP pool, at least in the tested 
experimental set-up. Even less 8-oxo-(d)GTPase and 2-OH-(d)ATPase activity of the 
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structurally related NUDT17 and NUDT18 suggests that MTH1 is the most prominent 
sanitizer of these oxidized nucleotides known today.  
To understand the cellular function of NUDT15, we performed a substrate screen with 
various endogenous and synthetic nucleotide species. While NUDT15 possessed low 
enzymatic activity with dTTP, dCTP and 8-oxo-dGTP, slightly higher activity was observed 
with dGTP. Interestingly, this substrate screen unraveled that the active thiopurine 
metabolites 6-thio-dGTP and 6-thio-GTP are good substrates for NUDT15 (Figure 12G). 
These data offered the first biochemical explanation for the observed thiopurine 
hypersensitivity in patients with NUDT15 mutations.  
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Figure 12: Main results of Paper III “Crystal structure, biochemical and cellular activities 
demonstrate separate functions of MTH1 and NUDT15”. A) NUDT15, NUDT17 and NUDT18 
possess limited activity with (oxidized) purines, when compared to MTH1 B) NUDT15 shows limited 
activity with the oxidized nucleotide 8-oxo-dGTP. C) Despite an overall similar structure, a shift in 
the α2 helix of NUDT15 creates a considerably shallower putative binding pocket. D) MTH1 forms a 
strong hydrogen bonding network with 8-oxo-dGMP, involving the residues Asp119 and Asp120. 
Trp136 and Gly137, which occupy equivalent positions in the NUDT15 structure, do not possess 
hydrogen bond possibilities. E) Depletion of NUDT15 had no effect on cell survival and did not 
increase the phenotype of MTH1 depletion. F) In contrast to MTH1, NUDT15 depletion did not 
increase 8-oxo-d levels in DNA, as assessed by the modified comet assay. G) A substrate screen 
identified the thiopurine effector metabolites, 6-thio-dGTP and 6-thio-GTP, as novel NUDT15 
substrates. 
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Paper IV: NUDT15 mediates the cellular efficacy of 6-thioguanine by hydrolyzing 
6-thio-(d)GTP 
Recently, several pharmacogenetic studies have uncovered a link between thiopurine 
hypersensitivity and the NUDT15 variant R139C [190, 193-201]. While investigating in the 
cellular function of NUDT15 we identified 6-thio-dGTP and 6-thio-GTP as novel substrates 
for the Nudix enzyme, offering the first biochemical explanation for the clinical data 
(Paper III). In the light of these findings, we aimed to understand 1) the role of NUDT15 in 
thiopurine metabolism and 2) the consequence of the arginine to cysteine substitution at 
position 139 of NUDT15 for thiopurine sensitivity. 
For this purpose, we performed extensive in vitro kinetic analyses to characterize the 
substrate preference of NUDT15. These studies confirmed that NUDT15 hydrolyzes both 
6-thio-dGTP and 6-thio-GTP, and as a result of increased substrate affinity prefers the 
thiolated over the canonical nucleotides dGTP and GTP (Figure 13A-B). To understand this 
substrate preference we identified the co-crystal structure of NUDT15 in complex with the 
6-thio-GTP hydrolysis product 6-thio-GMP. The steric fit and the accommodation of the 
6-thio moiety in the hydrophobic pocket explain the lower KM values of NUDT15 for the 
thiolated over canonical nucleotides.  
We hypothesized that the observed thiopurine hypersensitivity of patients expressing the 
NUDT15 variant R139C might be a result of enzymatic inactivity. However, we found that 
substituting arginine at position 139 to cysteine does not impair the enzymatic activity of 
NUDT15, but instead negatively influences protein stability. Thermal stability experiments 
indicated that loss of the ionic interaction between Arg139 and Asp132 leads to reduced 
protein stability. In line with this, ectopic overexpression of NUDT15 wild type and R139C 
in cancer cells resulted in comparable mRNA expression, but reduced protein levels for the 
R139C variant. Addition of the proteasome inhibitor MG-132 increased the NUDT15 R139C 
protein levels (Figure 13C). These experiments suggest that proteasomal degradation of the 
unstable NUDT15 variant R139C leads to reduced NUDT15 protein levels, preventing 
sanitation of 6-thio-(d)GTP and thereby causing thiopurine hypersensitivity.   
We next investigated whether the thiopurine hypersensitivity observed in patients expressing 
NUDT15 R139C, can be mimicked by shRNA-mediated depletion of NUDT15. Whereas 
knockdown of NUDT15 had no profound effect on cellular viability, it significantly 
potentiated 6-TG-induced cytotoxicity (Figure 13D).  
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The effect of NUDT15 depletion on 6-TG sensitivity was found in the MMR-proficient 
HCT-116 3/6 cells and in their MMR-deficient counterpart HCT-116, even though to a lesser 
extent.  
Altogether, these data highlight that NUDT15 is an important mediator of thiopurine 
sensitivity due to the hydrolyzing activity with the effector metabolites 6-thio-dGTP and 
6-thio-GTP (Figure 13E). Furthermore, we suggest that NUDT15 R139C is degraded under 
cellular conditions, rendering the patients expressing this variant hypersensitive to thiopurine 
therapy.  
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Figure 13: Main results of Paper IV “NUDT15 mediates the cellular efficacy of 6-thioguanine by 
hydrolyzing 6-thio-(d)GTP”. A) Kinetic analyses revealed that NUDT15 WT and B) NUDT15 R139C 
prefer thiolated guanine over the endogenous species dGTP. C) Overexpressed NUDT15 R139C was 
found to be unstable under cellular conditions, which could be rescued by addition of the proteasome 
inhibitor MG-132. D) Depletion of NUDT15 sensitized MMR-proficient (HCT116 3/6) and 
MMR-deficient (HCT116) cells to 6-TG treatment. E) NUDT15 is a major player in thiopurine 
metabolism due to its activity with the effector metabolites 6-thio-dGTP and 6-thio-GTP. 
  
  45 
Paper V: Targeting NUDT15 with small molecule inhibitors to increase thiopurine 
efficacy 
Encouraged by the clinical and experimental data demonstrating that NUDT15 activity 
influences 6-TG sensitivity, we aimed to develop first-in-class inhibitors of NUDT15 to 
validate the Nudix enzyme as a potential drug target to increase thiopurine efficacy.  
First, we confirmed that NUDT15 is an important mediator of thiopurine sensitivity in AML 
cells, by utilizing shRNA-mediated protein depletion. Importantly, overexpression of 
NUDT15 wild type, but not the catalytic dead (E67A) or unstable (R139C) protein variant, 
rescued the cytotoxicity induced by NUDT15 depletion, confirming on target effects of the 
shRNA.   
Subsequently, 17.946 compounds were screened for their inhibitory activity of NUDT15 
(Figure 14A). Extensive hit-to-lead optimization led to the development of several potent 
small molecule inhibitors of NUDT15, possessing desirable in vitro ADME properties. 
Whereas the developed NUDT15 inhibitors did not affect cellular viability alone, they 
significantly sensitized AML cells to 6-TG treatment, confirming data obtained by NUDT15 
knockdown (Figure 14B-C).  No effect of NUDT15 inhibition was found on the sensitivity 
of four ALL cell lines to 6-TG treatment.  Genetic modifications in MMR-associated genes 
might be one explanation for the lack of sensitization, which was supported by the use of the 
MMR-deficient cell line HCT116 and their MMR-proficient isogenic counterpart HCT116 
3/6.  
We next investigated the mode of action of the combination treatment NUDT15 inhibitors 
and 6-TG. HPLC experiments demonstrated that inhibition of NUDT15 prevents hydrolysis 
of 6-thio-GppCp in cellular lysates. The accumulation of thiolated triphosphates upon 
NUDT15 inhibition caused increased mis-incorporation of 6-thio-dGTP and 6-thio-GTP into 
DNA and RNA, respectively (Figure 14D-E). This was associated with potentiation of 6-TG 
induced DNA damage and cytotoxicity (Figure 14F).  
Overall, we here presented the development of the first-in-class small molecule inhibitors of 
NUDT15 and demonstrated that NUDT15 inhibition potentiates the cellular effect of 6-TG, 
including accumulation of thioguanosine triphosphate species, mis-incorporation into DNA 
and RNA, DNA damage and cell toxicity. Besides being valuable tools to unravel the 
physiological function of NUDT15, these compounds could improve the efficacy of 
thiopurines in patients.  
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Figure 14: Main results of Paper V “Targeting NUDT15 with small molecule inhibitors to increase 
thiopurine efficacy”. A) A malachite green-based screen was performed to identify compounds with 
inhibitory potential towards NUDT15. Subsequent medicinal chemistry and lead optimization led to 
the development of first-in-class NUDT15 inhibitors. B) NUDT15 inhibition did not affect cell 
viability (LD50) as a mono-treatment, but significantly sensitized cells to 6-TG treatment (EC50). C) 
Combination treatment with NUDT15 inhibitors increased the cellular sensitivity to 6-TG. D) 
NUDT15 inhibition augmented incorporation of the active metabolites 6-thio-dGTP and 6-thio-GTP 
into DNA and E) RNA, respectively. F) Inhibition of NUDT15 enhanced 6-TG-induced DNA damage.  
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2.4 Discussion and future perspectives 
The therapeutic efficacy of many anti-cancer agents remains variable, unpredictable and often 
limited by debilitating side effects and drug resistance. To improve anti-cancer therapy it is, 
on the one hand, important to identify novel drug targets and treatment strategies. On the 
other hand, research should strive on validating key players involved in existing treatments, 
which can improve the efficacy of current state-of-the-art therapies.  
Disturbing nucleotide homeostasis and genome integrity has been proven a valid point of 
attack, both in old and novel treatment approaches. Nucleobase- and nucleoside-analogs 
stand the test of time and remain an important cornerstone in various anti-cancer treatment 
regimens. Due to their resemblance to endogenous nucleotides, these antimetabolites enter 
the purine and pyrimidine salvage pathways and compete with canonical DNA and RNA 
building blocks. However, nucleotide metabolism is complex and the products are not only 
essential for DNA and RNA synthesis, but also for intracellular metabolism and signaling. It 
is therefore not surprising that the mechanism of action of the antimetabolites 5-FU, 
decitabine and 6-TG is multifaceted and even today not fully understood. A better 
understanding of their metabolism and mechanism of action could help to improve their 
therapeutic efficacy.  
One component influencing the potency of nucleobase- and nucleoside-analogs is the 
inactivation of their active triphosphate derivatives by nucleotide hydrolases. In this study, we 
shed light on the metabolism and mode of action of 5-FU, decitabine and 6-TG by 
investigating the importance of their degradation by nucleotide hydrolases. We validated 
whether targeting the activity of dUTPase, dCTPase and NUDT15 is a promising strategy to 
improve the sensitivity to these commonly used chemotherapeutic agents. The development 
of small molecule inhibitors made it possible to characterize the importance of these 
(d)NTPases in nucleotide homeostasis and cellular integrity, both alone and in the aspect of 
antimetabolite therapy. 
dUTPase 
To shed light on the working mechanism of commonly used fluoropyrimidines we analyzed 
5-FU-induced replication defects and the influence of dUTPase activity on these. We 
demonstrated that 5-FU treatment leads to a reduced replication fork speed. Inhibition of 
dUTPase accentuated the replication defects, as well as the cytotoxicity. These data support 
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that toxicity of 5-FU is, at least partially, attributable to intracellular accumulation of 
5-fluoro-dUTP and dUTP, mis-incorporation into DNA and subsequent replication defects.  
Despite extending the knowledge about the mode of action of fluoropyrimidines, we also 
highlight the benefit of dUTPase inhibitors to increase the therapeutic efficacy of 5-FU 
therapy. We have demonstrated that dUTPase inhibitors, as well as dUTPase depletion, 
significantly potentiate the replication defects and cellular toxicity of 5-FU. The notion that 
dUTPase is a good combination target for TS-directed therapies is supported by a number of 
studies that demonstrated a negative correlation between dUTPase expression and therapeutic 
outcome [41, 143-148]. The benefit of this combination therapy is therefore most likely 
dependent on the molecular make-up of the cell.  
Furthermore, we investigated the importance of dUTPase activity for cellular integrity. 
dUTPase depletion resulted in a small increase in cell debris, but no difference in long-term 
survival could be detected by colony formation assay. In line with this, dUTPase inhibitors 
did not impair cell viability after a treatment period of 72 hours. These experiments indicate 
that inhibition of dUTPase activity does not induce severe cytotoxicity, at least at the time 
points and set-ups tested. Upregulation of thymidylate kinase and thymidine kinase, resulting 
from a feedback mechanism to counteract dUTPase inhibitor-induced dTTP depletion, could 
prevent profound consequences of dUTPase inhibitors alone [144]. The lack of toxicity 
induced by dTUPase inhibition is supported by successful clinical phase one trials with the 
dUTPase inhibitor TAS-144. These demonstrated both, a favorable safety profile and 
desirable pharmacokinetic parameters [203].  
Several new implications for dUTPase inhibitors have recently been suggested. Chen et al. 
showed that the activity of dUTPase impacts ribonucleotide reductase-induced genome 
instability [204]. In addition, Requena et al. suggested that dUTPase reduces decitabine 
efficacy [48]. The development and characterization of dUTPase inhibitors will further 
facilitate research on the biological function and importance of dUTPase, both in endogenous 
and therapeutic nucleotide metabolism. This could open up novel implications for dUTPase 
inhibitors in the treatment of cancer and other diseases.  
In summary, we demonstrated the importance of (5-fluoro-)dUTP and dUTPase activity for 
5-FU treatment efficacy and thereby extend our current understanding of the mode of action. 
Especially with the development of several small molecule inhibitors of dUTPase and the 
first clinical trials, this treatment approach could soon improve the treatment response of 
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patients to TS-based therapy [203, 205, 206]. With this study, we support that targeting the 
hydrolase dUTPase is a promising strategy to increase 5-FU efficacy.  
dCTPase 
The nucleotide hydrolase dCTPase remains quite unstudied, but recent data suggest a role in 
nucleotide homeostasis and carcinogenesis. By hydrolyzing deoxycytidine and 5-modified 
deoxycytidine triphosphates dCTPase has been suggested to sanitize 1) halogenated 
nucleotides during inflammation 2) epigenetically involved 5-methyl-dCTP and 
5-formyl-dCTP and 3) the active decitabine derivative 5-aza-dCTP. By developing and 
characterizing the potent dCTPase inhibitor, TH1217, we provide the possibility to further 
explore dCTPase biology in these contexts. We showed that inhibition of dCTPase increases 
intracellular dCTP levels. However, this imbalance had no impact on DNA replication and 
cellular viability. Chronic treatment with TH1217, on the other hand, had a cytostatic effect 
on various cancer cell lines. This could result from epigenetic changes induced by reduced 
sanitation of 5-methyl-dCTP and 5-formyl-dCTP when dCTPase is inhibited. However, no 
changes in 5-methyl-dC could be detected in DNA after 1 and 6 days of TH1217 treatment. 
Overall, the physiological function of dCTPase remains to be uncovered. The development of 
TH1217 will facilitate the research on the role of dCTPase in nucleotide homeostasis and in 
epigenome fidelity. In addition, we supported a current study that highlighted the importance 
of dCTPase in decitabine metabolism [48]. The dCTPase inhibitors could therefore open up 
novel opportunities to increase the efficacy of decitabine treatment.  
NUDT15 
Besides improving the efficacy of commonly used chemotherapeutic agents it is of great need 
to identify novel anti-cancer targets to remove cancer from the “major cause of death”-list. 
Exploiting the disturbed redox environment of many cancers, by targeting sanitation of 
endogenously damaged nucleotides, has gained increasing interest as novel anti-cancer 
strategy. We and others have shown that cancer cells rely on sanitation of the oxidized 
nucleotide pool and that targeting the 8-oxo-dGTPase MTH1 is a promising target for cancer 
therapy [71, 77-80].  
Based on the increasing interest for enzymes involved in sanitation of the oxidized nucleotide 
pool, we investigated whether additional Nudix family members possess activity with 
oxidized adenine or guanine nucleotides (Paper III). We assessed the activity of the MTH1 
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sequence homologs NUDT15, NUDT17 and NUDT18 with 8-oxo-(d)GTP and 
2-OH-(d)ATP. Among these Nudix enzymes, the closest MTH1 sequence homolog NUDT15 
(MTH2) possessed the highest enzymatic activity with the tested substrates and was therefore 
further characterized. Detailed enzymatic characterization suggested that NUDT15 is a poor 
8-oxo-dGTPase. Opposite to MTH1, NUDT15 knockdown did not increase 8-oxo-dG levels 
in DNA and was not relevant for cancer cell survival, under the conditions tested. These data 
suggest that NUDT15, despite its sequence homology to MTH1, is not involved in 
8-oxo-(d)GTP sanitization in cells, making MTH1 the most prominent sanitizer of the 
oxidized nucleotide pool known to date.  
Since NUDT15 displayed a 9 times greater kcat/KM for dGTP over 8-oxo-dGTP, we tested the 
activity of NUDT15 with the canonical nucleotide at a physiologically relevant concentration 
(5 µM) [207, 208]. In depth kinetic analysis could not confirm NUDT15-catalyzed hydrolysis 
at these concentrations. However, regional accumulation or the activity in a certain biological 
context should not be excluded at this time. In addition, nucleotide metabolism is complex 
and regulated by the tight interplay of multiple enzymes, which could back up or reshuffle 
nucleotide homeostasis upon NUDT15 depletion. 
To unravel the cellular function and substrate of NUDT15 we screened NUDT15 activity 
with a panel of potential Nudix substrates (Paper III). During this screen, we identified the 
active thiopurine derivatives, 6-thio-dGTP and 6-thio-GTP, as novel NUDT15 substrates. 
This finding was especially interesting in the light of recently published pharmacogenic 
studies, which linked thiopurine hypersensitivity to the NUDT15 variant R139C.  
We therefore characterized the importance of NUDT15 in thiopurine metabolism and 
investigated the influence of NUDT15 mutations on this function (Paper IV). Our studies 
revealed that NUDT15 activity reduces treatment sensitivity, by hydrolyzing the effector 
metabolites 6-thio-dGTP and 6-thio-GTP. We furthermore suggest that the NUDT15 R139C 
variant is unstable in a cellular setting and subsequent accumulation of 6-thio-(d)GTP is the 
cause for thiopurine hypersensitivity. These findings support a recent study by Moriyama et 
al. that showed the involvement of NUDT15 (wild type and mutants) in thiopurine 
metabolism [209].  
Our data and the pharmacogenetic studies strongly suggest introducing pre-treatment 
screenings into the routine of thiopurine therapy, to identify patients with unstable NUDT15 
variants and subsequently adjust the treatment dose to prevent over-dose-induced side effects. 
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Right now, the unstable NUDT15 variants are considered risk factors for increased side 
effects, like leukopenia and hair loss. However, these observations could also be exploited to 
open the road for a novel treatment strategy: combining thiopurine treatment with NUDT15 
inhibitors.  
Encouraged by this idea we decided to develop inhibitors against NUDT15 to validate the 
approach of targeting NUDT15 to increase thiopurine efficacy. In Paper V we presented the 
development of the first-in-class NUDT15 inhibitors and demonstrated how these can be 
utilized to increase the sensitivity to thiopurine therapy. The developed compounds will be 
valuable to further unravel NUDT15 biology, both alone and in the context of 
nucleotide-analog treatment.  
One has to note that thioguanine triphosphates are not endogenously occurring nucleotides 
and therefore, the physiological function and the natural substrate of NUDT15 remain to be 
elucidated. The cellular data in Paper III, IV and V highlighted that both knockdown and 
inhibition of NUDT15 does not lead to a discernable phenotype. Knockdown of NUDT15 
using siRNA or shRNA did not affect cell cycle progression, DNA damage nor cell viability 
of the cancer cell lines tested (Paper III and Paper IV). Also the developed NUDT15 
inhibitors did not alter cell cycle progression, replication or viability at the time-points and in 
the cell lines tested (Paper V). The lack of importance of NUDT15 for cellular integrity is 
supported by the fact that the patients positive for NUDT15 R139C possess no increased risk 
for disease and appear healthy.   
Besides research on improving existing chemotherapeutic agents, an open mindset and basic 
research is needed to develop novel cancer-specific therapies. The research on the Nudix 
enzymes MTH1 and NUDT15 are good examples for this. Validating the importance of 
MTH1 for cancer cell survival has led to the development of new therapeutic strategies and 
novel, highly promising anti-cancer drugs. Characterization of the MTH1 sequence homolog 
NUDT15 could have provided an additional treatment strategy to prevent sanitation of the 
oxidized nucleotide pool. Instead, these studies revised our knowledge about the protein’s 
function and unraveled a previously unknown player in thiopurine metabolism.  
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Summary 
In summary, these studies emphasize that hydrolysis of the active triphosphate derivatives of 
nucleobase- and nucleoside-analogs significantly reduces their treatment efficacy. Inhibiting 
(d)NTPases involved in this degradation is an attractive strategy to increase treatment 
sensitivity.  
For the studies present here one question remains: whether these combination approaches will 
increase the treatment efficacy in cancer cells and simultaneously prevent adverse effects. In 
vivo absorption, distribution, metabolism and excretion (ADME) of the small molecule 
inhibitors will influence the degree of exposure for healthy and cancer cells. Additional 
research is needed to assess whether the proposed combination therapies will increase the 
therapeutic index and provide a benefit for the patient. The upregulation or deregulation of 
dUTPase, dCTPase and NUDT15 in certain tissues and cancers suggest an important role for 
these hydrolases during carcinogenesis. In addition, this offers an opportunity to increase the 
therapeutic index for antimetabolite therapy by adding dUTPase, dCTPase and NUDT15 
inhibitors to the treatment regimen.  
Numerous additional antimetabolites have been developed that antagonize 
(deoxy)ribonucleotide metabolism. Many of which have successfully been used in the 
treatment of cancer and also as anti-viral or immunosuppressive agents. These include among 
others the pyrimdine-analogs cytarabine, gemcitabine, lamivudine and zidovudine and the 
purine-analogs fludarabine, cladribine, clofarabine, acyclovir and ganciclovir [23]. 
Identification of novel substrates and biological functions of these hydrolases could open up 
new avenues for therapeutic intervention, not only for anti-cancer treatment. 
In addition, innovative research on endogenously occuring nucleotides and their potential to 
disturb cancer cell integrity is of great interest to identify novel, cancer-specific therapy. The 
recently discovered 5-formyl-dC and the connected hypersensitivity of CDA overexpressing 
tumors are good examples of novel anti-cancer strategies exploiting the damaged nucleotide 
pool [53-57].  
Overall, we show that preventing the sanitation of nucleotide-analogs by inhibiting 
nucleoside triphosphate hydrolases is a promising strategy to improve the efficacy of 
nucleobase- and nucleoside-analog treatments. In addition, the developed dUTPase, dCTPase 
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and NUDT15 inhibitors are valuable tools to unravel the importance of these hydrolases in 
endogenous and therapeutic nucleotide homeostasis.  
 
Figure 15: Examples of how (d)NTPases can be targeted to increase antimetabolite efficacy. In this 
thesis were covered: A) targeting dUTPase to potentiate 5-fluorouracil treatment, B) targeting 
dCTPase to potentiate decitabine treatment and C) targeting NUDT15 to potentiate 6-thioguanine 
treatment. Inhibiting the hydrolases dUTPase, dCTPase and NUDT15 prevents the hydrolysis of the 
nucleoside triphosphate analogs derived from 5-FU, 5-aza-dC and 6-TG, respectively. Increased 
availability of the triphosphate species leads to mis-incorporation into DNA (and for certain species 
into RNA) causing overall DNA damage and cytotoxicity.   
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